Next-Gen Gene Therapy Firm Kate Therapeutics Starts Out With Big Pharma Partner
Announces $51m Series A, License Deal With Astellas
Kate is focused on delivering gene therapies for two rare, neuromuscular diseases by deploying AAV technology that it says will target muscle tissue and enable regulated therapeutic payloads.
